Cell Source's EPS (Basic) for the
three
months ended in Dec. 2024 was $-0.01.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.13.
Cell Source's EPS without NRI for the
three
months ended in Dec. 2024 was $-0.02.
Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.14.
Cell Source (OTCPK:CLCS) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Cell Source Earnings per Share (Diluted) Related Terms
Cell Source Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Cell Source's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLCS vs EDSA, CTXR, ASBP: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Cell Source's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cell Source PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cell Source's PE Ratio distribution charts can be found below:
* The bar in red indicates where Cell Source's PE Ratio falls into.
Cell Source Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Cell Source's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2024 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.13
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.13 mean?
Cell Source (CLCS) has a Earnings per Share (Diluted) of $-0.13 as of Dec. 2024. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Cell Source and its competitors.
Is Cell Source's Earnings per Share (Diluted) too high?
Cell Source's current Earnings per Share (Diluted) is $-0.13. Overall, Cell Source has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cell Source's Earnings per Share (Diluted) compare to EDSA and CTXR?
Cell Source's Earnings per Share (Diluted) of $-0.13 can be compared against companies in the Biotechnology industry. The industry median Earnings per Share (Diluted) is 16.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.40, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Cell Source and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cell Source's current Earnings per Share (Diluted) is $-0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Source stock overvalued right now?
Cell Source (CLCS) has a current Earnings per Share (Diluted) of $-0.13. The current Earnings per Share (Diluted) is $-0.13. Cell Source's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Cell Source (CLCS), the current Earnings per Share (Diluted) is $-0.13 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.
35GF Score
Get the complete analysis for CLCS
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLCS has been successfully added to your 
